H.C. Wainwright initiated coverage of Actuate Therapeutics (ACTU) with a Buy rating and $20 price target Actuate is a clinical-stage ...

Fintel reports that on March 17, 2025, HC Wainwright & Co. initiated coverage of Actuate Therapeutics (NasdaqGM:ACTU) with a ...

Actuate Therapeutics , Inc., a biopharmaceutical company with a market capitalization of $172 million, announced today that it will hold its first Annual Meeting of Stockholders virtually on May ...

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for ...

Actuate Therapeutics has a 52-week low of $5.51 and a 52-week high of $11.73. The business’s 50-day simple moving average is $8.34 and its 200 day simple moving average is $8.17. Actuate ...

The benefit is huge because millions of businesspeople may not know the niceties of databases or back-end applications, but they know Excel and how to use it, said Actuate executives. "The benefit ...